The Patent Finder

Oxxon Therapeutics Limited

Also on record
Records under this name other than patents Oxxon Therapeutics Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 6 of 6 · Back to Oxxon Therapeutics Limited

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,407,661Methods and reagents that generate a CD8 T cell immune response
Term ended
Term ended Dec 1, 2018 · USPTO record
Term endedTerm ended Dec 1, 2018USPTO record
US 7,514,087Methods and reagents for immunization which generate a CD8 T cell immune response
Term ended
Term ended Sep 5, 2018 · USPTO record
Term endedTerm ended Sep 5, 2018USPTO record
US 6,663,871Methods and reagents for vaccination which generate a CD8 T cell immune response
Formerly held
Term ended
Term ended Jun 9, 2018 · USPTO record
Term endedTerm ended Jun 9, 2018USPTO record
US 7,384,643Recombinant poxvirus
Lapsed on the fee record
Ended Jun 10, 2012 · USPTO record
Lapsed on the fee recordEnded Jun 10, 2012USPTO record
US 6,355,252Soluble vaccinia virus protein that binds chemokines
Lapsed on the fee record
Ended Mar 12, 2010 · USPTO record
Lapsed on the fee recordEnded Mar 12, 2010USPTO record
US 5,972,351Plasmodium falciparum MHC class I-restricted CTL epitopes derived from pre-erythrocytic stage antigens
Term ended
Term ended no later than Oct 26, 2019 · Low confidence
Term endedTerm ended no later than Oct 26, 2019Low confidence
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited